News | Breast Imaging | June 06, 2018

More Breast Cancers Found With Combined Digital Screening

More Breast Cancers Found With Combined Digital Screening in breast imaging.

A combination of digital mammography and tomosynthesis detects 90 percent more breast cancers than digital mammography alone, according to a study appearing online in the journal Radiology.[1]

Digital breast tomosynthesis (DBT) is an imaging technology that uses a series of low-dose mammographic exposures to provide a 3-D reconstruction of the breast. In studies comparing both technologies on the same women, DBT has proven to be more sensitive than digital mammography in detecting cancers. Despite DBT's superior sensitivity, some groups caution that it could detect cancers that will never be clinically relevant -- a phenomenon known as overdiagnosis.

To learn more about DBT's impact on sensitivity and recall rate, or the rate at which women are called back for additional screening based on suspicious results, researchers compared results between 9,777 women randomized to undergo digital mammography and DBT and 9,783 randomized to have digital mammography alone.

The combination of digital mammography and DBT detected 8.6 cancers per 1,000 cases, a rate almost twice that of the 4.5 per 1,000 detected by mammography alone. The recall rate was 3.5 percent in both groups. DBT alone detected 72 of 80 cancers found in the DBT and digital mammography group. The greater detection rate for combined digital mammography and DBT was notable for small and medium invasive cancers, but not for large ones.

"Tomosynthesis and digital mammography is much more sensitive than digital mammography," said the study's principal investigator, Pierpaolo Pattacini, M.D., radiologist and director of the Radiology Department at AUSL Reggio Emilia in Reggio Emilia, Italy. "The vast majority of the advantage is due to tomosynthesis alone."

While DBT's higher sensitivity would seem to make it a logical choice for breast cancer screening programs, coauthor Paolo Giorgi Rossi, Ph.D., director of the Epidemiology Unit at AUSL Reggio Emilia said that more research is needed to weigh the benefits of improvements in prognosis and reductions in breast cancer-related mortality from DBT against any undesired effects.

"If these small cancers would never become life-threatening, then we are increasing overdiagnosis and not impacting mortality," he said. "Thus, we need to have a measure of the impact of this higher detection rate on the incidence of advanced cancers and interval cancers in the following years."

The additional reading time DBT would require from breast imagers is another aspect of the technology that requires consideration, according to Rossi.

"For publicly-funded screening programs, this increased reading time would be a big issue, destroying their sustainability," he said. "Implementing tomosynthesis in public screening programs would require rethinking protocols and reading technologies to reduce or eliminate the extra costs."

The new research represents a preliminary analysis from the Reggio Emilia Tomosynthesis trial (RETomo), a larger study in which researchers will be looking at interval cancers, or those detected between screening exams, and cumulative incidence of advanced cancers. To have more precise and reliable estimates of these outcomes, the researchers are promoting a network of ongoing trials on tomosynthesis with similar study design across Europe.

"Once we have this evidence, the consequences for screening could be even larger than a simple shift from digital mammography to tomosynthesis," Rossi said. "For example, it could be appropriate to adopt longer intervals between screenings."

 

Reference:

1. Pierpaolo Pattacini, Andrea Nitrosi, Paolo Giorgi Rossi, et al. Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial. Radiology. Published Online June 5 2018. https://doi.org/10.1148/radiol.2018172119.
 

 

Related Content

Nuance Launches Cloud-Based mPower Clinical Analytics Platform at AHRA 2018
Technology | Analytics Software | August 16, 2018
At the Association for Medical Imaging Management (AHRA) 2018 Annual Meeting and Exposition, July 22-25 in Orlando, Fla...
Intel and Philips Demonstrate CPU Ability in Deep Learning Inference Test Cases
News | Artificial Intelligence | August 15, 2018
Intel and Philips recently tested two healthcare uses for deep learning inference models using Intel Xeon Scalable...
Fujifilm SonoSite Unveils Full Suite of iViz Point-of-Care Transducers

The L25v ultrasound transducer for the Fujifilm Sonosite iViz is available for superficial applications such as ophthalmic, arterial, venous, lung and nerve. Image courtesy of Fujifilm Sonosite.

Technology | Ultrasound Imaging | August 15, 2018
Fujifilm SonoSite Inc. announced the launch of two new transducers for the SonoSite iViz point-of-care ultrasound, now...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
Indiana Hospital Installs First Vantage Titan/Zen Edition 1.5T MRI in U.S.
News | Magnetic Resonance Imaging (MRI) | August 10, 2018
Patients in Pulaski County, Ind., now have access to quiet, comfortable magnetic resonance (MR) exams thanks to the...
Visage Signs Mercy for Visage 7 Open Archive
News | Enterprise Imaging | August 09, 2018
Visage Imaging Inc. announced that it has signed a seven-year contract with Mercy, the fifth largest Catholic health...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Aidoc Receives FDA Clearance for AI Detection of Acute Intracranial Hemorrhage
Technology | Clinical Decision Support | August 08, 2018
Aidoc announced that it was granted U.S. Food and Drug Administration (FDA) clearance for the first product of its...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Overlay Init